Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

diagnosis-to-treatment interval

  • Home
  • diagnosis-to-treatment interval
Impact of Diagnosis-to-Treatment Interval on Outcomes in Follicular Lymphoma Undergoing Immunochemotherapy
Posted inHematology-Oncology news Oncology

Impact of Diagnosis-to-Treatment Interval on Outcomes in Follicular Lymphoma Undergoing Immunochemotherapy

Posted by MedXY By MedXY 06/30/2026
Shorter diagnosis-to-treatment intervals independently predict worse outcomes in follicular lymphoma treated with immunochemotherapy, highlighting a novel prognostic factor beyond existing risk indices.
Read More
  • Unraveling Immune Dysfunction in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma: The Role of Systemic Antiviral Loss and Myeloid Suppression
  • Impact of Diagnosis-to-Treatment Interval on Outcomes in Follicular Lymphoma Undergoing Immunochemotherapy
  • Empowering Climate-Conscious Inhaler Prescribing: A Patient-Physician Conversation Aid
  • Hypoxic Microenvironment Triggers Early Aggressive Progression in EGFR-Mutant Lung Adenocarcinoma
  • Posterior Segment Risk Factors Influencing Penetrating Keratoplasty Graft Survival
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis prostate cancer public health quality of life randomized clinical trial randomized trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in